GRAMD2A and breast cancer: Our exome wide analysis revealed only seven genes (ASP, C17orf80, FAM111B, GRAMD2, SP100, USP45 and ZNF534) with high impact mutations (PDAVs) in three (or more) BC patients while comparable mutations were not found (or only once) among the control samples.